ADVERTISEMENT
Videos
Rucaparib Promising for BRCA–Positive Relapsed Ovarian Cancer: Results From the ARIEL4 Trial
07/04/2021
David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA+, advanced, relapsed ovarian carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement